Y mAbs Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $22,798 | $19,931 | $23,363 | $20,454 |
Gross Profit | 19,784 | 17,784 | 21,324 | 17,809 |
EBITDA | -9,636 | -6,749 | -3,038 | -7,749 |
EBIT | -9,789 | -6,908 | -3,199 | -7,917 |
Net Income | -9,249 | -6,629 | -988 | -7,747 |
Net Change In Cash | 22,798 | 19,931 | 23,363 | 20,454 |
Free Cash Flow | 298 | -3,477 | -8,036 | -1,338 |
Cash | 77,806 | 75,749 | 78,637 | 86,571 |
Basic Shares | 44,022 | 43,779 | 43,627 | 43,620 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $84,819 | $65,267 | $34,897 | $20,750 |
Gross Profit | 73,403 | 57,700 | 32,383 | 18,547 |
EBITDA | -20,455 | -93,972 | -114,651 | -117,732 |
EBIT | -21,190 | -94,811 | -115,433 | -118,128 |
Net Income | -21,427 | -96,325 | -56,345 | -118,343 |
Net Change In Cash | 84,819 | 65,267 | 34,897 | 20,750 |
Cost of Revenue | 66,801 | -92,012 | ||
Free Cash Flow | -27,232 | -75,921 | -103,523 | -91,406 |
Cash | 78,637 | 105,762 | 181,564 | 114,634 |
Basic Shares | 43,645 | 43,703 | 43,181 | 40,118 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.21 |
2024-03-31 | -$0.15 |
2023-12-31 | -$0.02 |
2023-09-30 | -$0.18 |
